Literature DB >> 34239117

Biomaterial vaccines capturing pathogen-associated molecular patterns protect against bacterial infections and septic shock.

Michael Super1,2, Edward J Doherty1, Mark J Cartwright1, Benjamin T Seiler1, Fernanda Langellotto1, Nikolaos Dimitrakakis1, Des A White1, Alexander G Stafford1, Mohan Karkada1, Amanda R Graveline1, Caitlin L Horgan1, Kayla R Lightbown1, Frank R Urena1, Chyenne D Yeager1, Sami A Rifai1, Maxence O Dellacherie3, Aileen W Li3, Collin Leese-Thompson1, Hamza Ijaz1, Amanda R Jiang2, Vasanth Chandrasekhar1, Justin M Scott1, Shanda L Lightbown1, Donald E Ingber1,2,3, David J Mooney4,5.   

Abstract

Most bacterial vaccines work for a subset of bacterial strains or require the modification of the antigen or isolation of the pathogen before vaccine development. Here we report injectable biomaterial vaccines that trigger potent humoral and T-cell responses to bacterial antigens by recruiting, reprogramming and releasing dendritic cells. The vaccines are assembled from regulatorily approved products and consist of a scaffold with absorbed granulocyte-macrophage colony-stimulating factor and CpG-rich oligonucleotides incorporating superparamagnetic microbeads coated with the broad-spectrum opsonin Fc-mannose-binding lectin for the magnetic capture of pathogen-associated molecular patterns from inactivated bacterial-cell-wall lysates. The vaccines protect mice against skin infection with methicillin-resistant Staphylococcus aureus, mice and pigs against septic shock from a lethal Escherichia coli challenge and, when loaded with pathogen-associated molecular patterns isolated from infected animals, uninfected animals against a challenge with different E. coli serotypes. The strong immunogenicity and low incidence of adverse events, a modular manufacturing process, and the use of components compatible with current good manufacturing practice could make this vaccine technology suitable for responding to bacterial pandemics and biothreats.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34239117     DOI: 10.1038/s41551-021-00756-3

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   25.671


  2 in total

Review 1.  Immunologically active biomaterials for cancer therapy.

Authors:  Omar A Ali; David J Mooney
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  BCG Vaccination in HIV-Infected Children.

Authors:  James J C Nuttall; Brian S Eley
Journal:  Tuberc Res Treat       Date:  2011-04-10
  2 in total
  4 in total

Review 1.  Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy.

Authors:  Xuejiao Han; Aqu Alu; Hongmei Liu; Yi Shi; Xiawei Wei; Lulu Cai; Yuquan Wei
Journal:  Bioact Mater       Date:  2022-01-19

2.  Inorganic nanosheets facilitate humoral immunity against medical implant infections by modulating immune co-stimulatory pathways.

Authors:  Chuang Yang; Yao Luo; Hao Shen; Min Ge; Jin Tang; Qiaojie Wang; Han Lin; Jianlin Shi; Xianlong Zhang
Journal:  Nat Commun       Date:  2022-08-18       Impact factor: 17.694

Review 3.  Materials-based vaccines for infectious diseases.

Authors:  Yang Bo; Hua Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-06-16

4.  The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.

Authors:  Senta M Kapnick
Journal:  DNA Cell Biol       Date:  2021-12-24       Impact factor: 3.311

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.